Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CLNN
CLNN logo

CLNN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Clene Inc (CLNN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
5.730
1 Day change
1.06%
52 Week Range
13.500
Analysis Updated At
2026/03/20
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Clene Inc (CLNN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, has weak financial performance, and no strong trading signals. A 'hold' action is recommended until more favorable conditions arise.

Technical Analysis

The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 52.262, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level (5.896), with resistance at 6.505 and support at 5.287.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
5

Positive Catalysts

  • Gross margin increased by 26.09% YoY, showing some improvement in operational efficiency.

Neutral/Negative Catalysts

  • Revenue dropped by -82.76% YoY in Q3 2025, and EPS declined by -30.33% YoY. No recent news, no significant hedge fund or insider trading activity, and no recent congress trading data. The stock has a 40% chance of declining in the next day and month.

Financial Performance

In Q3 2025, revenue dropped significantly to 15,000 (-82.76% YoY). Net income improved slightly to -8,777,000 (+9.90% YoY), but EPS dropped to -0.85 (-30.33% YoY). Gross margin increased to 100 (+26.09% YoY). Overall, financials indicate weak growth trends.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Wall Street analysts forecast CLNN stock price to rise
5 Analyst Rating
Wall Street analysts forecast CLNN stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.730
sliders
Low
30
Averages
30.4
High
31
Current: 5.730
sliders
Low
30
Averages
30.4
High
31
Maxim
Naz Rahman
Buy
maintain
$20 -> $30
AI Analysis
2025-12-03
Reason
Maxim
Naz Rahman
Price Target
$20 -> $30
AI Analysis
2025-12-03
maintain
Buy
Reason
Maxim analyst Naz Rahman raised the firm's price target on Clene to $30 from $20 and keeps a Buy rating on the shares after the company and its wholly owned subsidiary Clene Nanomedicine announced completion of the FDA-recommended biomarker analyses for CNM-Au8 in people living with ALS. The results demonstrate statistically significant reductions in both neurofilament light, NfL, and glial fibrillary acidic protein, GFAP, which "clears way" for an NDA filing, the analyst says.
Benchmark
Buy
downgrade
$33 -> $31
2025-09-10
Reason
Benchmark
Price Target
$33 -> $31
2025-09-10
downgrade
Buy
Reason
Benchmark lowered the firm's price target on Clene to $31 from $33 and keeps a Buy rating on the shares. Having obtained agreement from the FDA regarding the statistical analysis plan, Clene continues to work toward an anticipated NDA submission in Q4 for CNM-Au-8 in the treatment of ALS, the analyst noted while updating the firm's model.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CLNN
Unlock Now

People Also Watch